{"id":"W2947828388","doi":"10.1200/jco.2019.37.15_suppl.tps601","title":"KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Pembrolizumab; Breast cancer; Epirubicin; Placebo; Oncology; Chemotherapy; Neoadjuvant therapy; Anthracycline; Cancer; Gastroenterology; Urology; Pathology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002235646,0.002991944,0.003200213,0.0006770645,0.0007303812,0.001533471,0.001864281,0.002752776,0.01445956],"category_scores_gemma":[0.001777195,0.0011255,0.001970728,0.0005376645,0.001763657,0.001690369,0.0005760352,0.004282647,0.002502293],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001289316,"about_ca_system_score_gemma":0.002591496,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001732368,"about_ca_topic_score_gemma":0.004779051,"domain_scores_codex":[0.9993242,0.000296872,0.00003524872,0.0001511508,0.00005528347,0.0001372917],"domain_scores_gemma":[0.9992099,0.0001557981,0.0001991903,0.00006310405,0.00005444034,0.0003175615],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9772769,0.01066662,0.0001471006,0.0005760239,0.0004755738,0.00001901288,0.00002864523,0.0001901877,0.002397361,0.0001231831,0.001193091,0.006906284],"study_design_scores_gemma":[0.9668518,0.03181025,0.0003462032,0.00002010505,0.0001513946,0.00001085503,0.00001000028,0.000168875,0.0001767038,0.00008545701,0.0003594809,0.000008883932],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9370962,0.007013179,0.002333247,0.001868389,0.002785992,0.03385002,0.006276814,0.0008754122,0.007900731],"genre_scores_gemma":[0.9357136,0.003865305,0.00491634,0.004798775,0.001018987,0.03524077,0.003561441,0.0001059152,0.01077884],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01445956,"threshold_uncertainty_score":0.04837203,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03627296762888955,"score_gpt":0.3865373696550671,"score_spread":0.3502644020261776,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}